TY - JOUR
T1 - Clinical impact of metformin in diabetic diffuse large B-cell lymphoma patients
T2 - a case-control study
AU - Alkhatib, Yaser
AU - Abdel Rahman, Zaid
AU - Kuriakose, Philip
N1 - Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/5/4
Y1 - 2017/5/4
N2 - Molecular studies have shown metformin to have a promising effect in lymphoma; however, there is lack of studies translating this effect into clinical settings. This was a case-control study to assess the clinical effect of metformin in diabetic diffuse large B-cell lymphoma (DLBCL) patients. Case subjects were diabetic on metformin with a new diagnosis of DLBCL. A total of 24 case subjects were identified, and for each case a control was matched. Outcomes of this study were to assess overall response rate, complete remission rate, progression free survival, and overall survival between the two groups. There was a significant increase in overall response rate, complete remission rate, and improved progression free survival in the metformin group compared to the control group, however, no significant overall survival difference was observed. Metformin use might be associated with an improved response rates and progression-free survival in diabetic DLBCL patients.
AB - Molecular studies have shown metformin to have a promising effect in lymphoma; however, there is lack of studies translating this effect into clinical settings. This was a case-control study to assess the clinical effect of metformin in diabetic diffuse large B-cell lymphoma (DLBCL) patients. Case subjects were diabetic on metformin with a new diagnosis of DLBCL. A total of 24 case subjects were identified, and for each case a control was matched. Outcomes of this study were to assess overall response rate, complete remission rate, progression free survival, and overall survival between the two groups. There was a significant increase in overall response rate, complete remission rate, and improved progression free survival in the metformin group compared to the control group, however, no significant overall survival difference was observed. Metformin use might be associated with an improved response rates and progression-free survival in diabetic DLBCL patients.
KW - AMPK
KW - Diffuse Large B-Cell Lymphoma (DLBCL)
KW - metformin
UR - http://www.scopus.com/inward/record.url?scp=84990186635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84990186635&partnerID=8YFLogxK
U2 - 10.1080/10428194.2016.1239822
DO - 10.1080/10428194.2016.1239822
M3 - Article
C2 - 27701994
AN - SCOPUS:84990186635
SN - 1042-8194
VL - 58
SP - 1130
EP - 1134
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5
ER -